Multiancestry genomic and transcriptomic analysis of gastric cancer.


Journal

Nature genetics
ISSN: 1546-1718
Titre abrégé: Nat Genet
Pays: United States
ID NLM: 9216904

Informations de publication

Date de publication:
04 2023
Historique:
received: 07 12 2020
accepted: 06 02 2023
medline: 17 4 2023
pubmed: 15 3 2023
entrez: 14 3 2023
Statut: ppublish

Résumé

Gastric cancer is among the most common malignancies worldwide, characterized by geographical, epidemiological and histological heterogeneity. Here, we report an extensive, multiancestral landscape of driver events in gastric cancer, involving 1,335 cases. Seventy-seven significantly mutated genes (SMGs) were identified, including ARHGAP5 and TRIM49C. We also identified subtype-specific drivers, including PIGR and SOX9, which were enriched in the diffuse subtype of the disease. SMGs also varied according to Epstein-Barr virus infection status and ancestry. Non-protein-truncating CDH1 mutations, which are characterized by in-frame splicing alterations, targeted localized extracellular domains and uniquely occurred in sporadic diffuse-type cases. In patients with gastric cancer with East Asian ancestry, our data suggested a link between alcohol consumption or metabolism and the development of RHOA mutations. Moreover, mutations with potential roles in immune evasion were identified. Overall, these data provide comprehensive insights into the molecular landscape of gastric cancer across various subtypes and ancestries.

Identifiants

pubmed: 36914835
doi: 10.1038/s41588-023-01333-x
pii: 10.1038/s41588-023-01333-x
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

581-594

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
doi: 10.3322/caac.21492 pubmed: 30207593
Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
doi: 10.3322/caac.21660 pubmed: 33538338
Parsonnet, J. et al. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325, 1127–1131 (1991).
doi: 10.1056/NEJM199110173251603 pubmed: 1891020
Kumar, S., Metz, D. C., Ellenberg, S., Kaplan, D. E. & Goldberg, D. S. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology 158, 527–536 (2020).
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C. & Lordick, F. Gastric cancer. Lancet 396, 635–648 (2020).
doi: 10.1016/S0140-6736(20)31288-5 pubmed: 32861308
Laurén, P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 64, 31–49 (1965).
doi: 10.1111/apm.1965.64.1.31 pubmed: 14320675
Laurén, P. A. & Nevalainen, T. J. Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer 71, 2926–2933 (1993).
doi: 10.1002/1097-0142(19930515)71:10<2926::AID-CNCR2820711007>3.0.CO;2-X pubmed: 8490820
Parsonnet, J. et al. Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas. J. Natl Cancer Inst. 83, 640–643 (1991).
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
doi: 10.1038/nature13480
Petrovchich, I. & Ford, J. M. Genetic predisposition to gastric cancer. Semin. Oncol. 43, 554–559 (2016).
doi: 10.1053/j.seminoncol.2016.08.006 pubmed: 27899187
Kang, B. W. & Chau, I. Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. ESMO Open 5, e000791 (2020).
pmcid: 7440716 doi: 10.1136/esmoopen-2020-000791 pubmed: 32817133
Kamariza, M., Crawford, L., Jones, D. & Finucane, H. Misuse of the term ‘trans-ethnic’ in genomics research. Nat. Genet. 53, 1520–1521 (2021).
doi: 10.1038/s41588-021-00952-6 pubmed: 34741159
Wang, K. et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat. Genet. 46, 573–582 (2014).
doi: 10.1038/ng.2983 pubmed: 24816253
Chen, K. et al. Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy. Proc. Natl Acad. Sci. USA 112, 1107–1112 (2015).
Liu, J. et al. Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer. Nat. Commun. 5, 3830 (2014).
doi: 10.1038/ncomms4830 pubmed: 24807215
Park, H. et al. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. Proc. Natl Acad. Sci. USA 112, 12492–12497 (2015).
Johansen, F. E. et al. Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice. J. Exp. Med. 190, 915–992 (1999).
pmcid: 2195652 doi: 10.1084/jem.190.7.915 pubmed: 10510081
Kakiuchi, N. et al. Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. Nature 577, 260–265 (2020).
doi: 10.1038/s41586-019-1856-1 pubmed: 31853061
Guimarães, D. S. & Gomes, M. D. Expression, purification, and characterization of the TRIM49 protein. Protein Expr. Purif. 143, 57–61 (2018).
doi: 10.1016/j.pep.2017.10.014 pubmed: 29107100
Tamborero, D. et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 10, 25 (2018).
pmcid: 5875005 doi: 10.1186/s13073-018-0531-8 pubmed: 29592813
Griffith, M. et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat. Genet. 49, 170–174 (2017).
pmcid: 5367263 doi: 10.1038/ng.3774 pubmed: 28138153
Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 2017, PO.17.00011 (2017).
pubmed: 28890946
Kataoka, K. et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 534, 402–406 (2016).
doi: 10.1038/nature18294 pubmed: 27281199
Jusakul, A. et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 7, 1116–1135 (2017).
pmcid: 5628134 doi: 10.1158/2159-8290.CD-17-0368 pubmed: 28667006
Shiraishi, Y. et al. A comprehensive characterization of cis-acting splicing-associated variants in human cancer. Genome Res. 28, 1111–1125 (2018).
pmcid: 6071634 doi: 10.1101/gr.231951.117 pubmed: 30012835
Kakiuchi, M. et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat. Genet. 46, 583–587 (2014).
doi: 10.1038/ng.2984 pubmed: 24816255
Zhang, H. et al. Gain-of-function RHOA mutations promote focal adhesion kinase activation and dependency in diffuse gastric cancer. Cancer Discov. 10, 288–305 (2020).
doi: 10.1158/2159-8290.CD-19-0811 pubmed: 31771969
Jaiswal, B. S. et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23, 603–617 (2013).
doi: 10.1016/j.ccr.2013.04.012 pubmed: 23680147
Boggon, T. J. et al. C-cadherin ectodomain structure and implications for cell adhesion mechanisms. Science 296, 1308–1313 (2002).
doi: 10.1126/science.1071559 pubmed: 11964443
Guilford, P. et al. E-cadherin germline mutations in familial gastric cancer. Nature 392, 402–405 (1998).
doi: 10.1038/32918 pubmed: 9537325
Ciriello, G. et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163, 506–519 (2015).
pmcid: 4603750 doi: 10.1016/j.cell.2015.09.033 pubmed: 26451490
Kievit, A. et al. Variants in members of the cadherin–catenin complex, CDH1 and CTNND1, cause blepharocheilodontic syndrome. Eur. J. Hum. Genet. 26, 210–219 (2018).
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pmcid: 3776390 doi: 10.1038/nature12477 pubmed: 23945592
Totoki, Y. et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46, 1267–1273 (2014).
doi: 10.1038/ng.3126 pubmed: 25362482
Chang, J. et al. Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. Nat. Commun. 8, 15290 (2017).
pmcid: 5477513 doi: 10.1038/ncomms15290 pubmed: 28548104
Li, H. et al. Geographically separate increases in the frequency of the derived ADH1B*47His allele in eastern and western Asia. Am. J. Hum. Genet. 81, 842–846 (2007).
Eng, M. Y., Luczak, S. E. & Wall, T. L. ALDH2, ADH1B, and ADH1C genotypes in Asians: a literature review. Alcohol Res. Health 30, 22–27 (2007).
pmcid: 3860439 pubmed: 17718397
Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019).
pmcid: 6954100 doi: 10.1038/s41586-019-1032-7 pubmed: 30894752
Blees, A. et al. Structure of the human MHC-I peptide-loading complex. Nature 551, 525–528 (2017).
doi: 10.1038/nature24627 pubmed: 29107940
Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443–455 (2020).
pmcid: 7182070 doi: 10.1016/j.ccell.2020.03.017 pubmed: 32289269
Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).
pmcid: 6718162 doi: 10.1126/science.aar3593 pubmed: 30309915
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
pmcid: 4856474 doi: 10.1016/j.cell.2014.12.033 pubmed: 25594174
Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017).
pmcid: 5531419 doi: 10.1172/JCI91190 pubmed: 28650338
Santos, J. C. et al. SOX9 elevation acts with canonical WNT signaling to drive gastric cancer progression. Cancer Res. 76, 6735–6746 (2016).
doi: 10.1158/0008-5472.CAN-16-1120 pubmed: 27569216
Togasaki, K. et al. Wnt signaling shapes the histologic variation in diffuse gastric cancer. Gastroenterology 160, 823–830 (2021).
doi: 10.1053/j.gastro.2020.10.047 pubmed: 33217450
Selvanathan, A. et al. CDH1 mutation distribution and type suggests genetic differences between the etiology of orofacial clefting and gastric cancer. Genes 11, 391 (2020).
pmcid: 7231129 doi: 10.3390/genes11040391 pubmed: 32260281
GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol. Hepatol. 5, 42–54 (2020).
WHO Classification of Tumours Editorial Board. (ed.) World Health Organization Classification of Tumours, 5th Edition: Digestive System Tumours (IARC, 2010).
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S. & Gajewski, T. F. WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin. Cancer Res. 25, 3074–3083 (2019).
pmcid: 6522301 doi: 10.1158/1078-0432.CCR-18-1942 pubmed: 30635339
Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
pmcid: 5007206 doi: 10.1056/NEJMoa1604958 pubmed: 27433843
Harrison, O. J. et al. The extracellular architecture of adherens junctions revealed by crystal structures of type I cadherins. Structure 19, 244–256 (2011).
pmcid: 3070544 doi: 10.1016/j.str.2010.11.016 pubmed: 21300292
Nardone, V. et al. Crystal structure of human E-cadherin-EC1EC2 in complex with a peptidomimetic competitive inhibitor of cadherin homophilic interaction. J. Med. Chem. 59, 5089–5094 (2016).
doi: 10.1021/acs.jmedchem.5b01487 pubmed: 27120112
Parisini, E., Higgins, J. M., Liu, J. H., Brenner, M. B. & Wang, J. H. The crystal structure of human E-cadherin domains 1 and 2, and comparison with other cadherins in the context of adhesion mechanism. J. Mol. Biol. 373, 401–411 (2007).
pmcid: 2094043 doi: 10.1016/j.jmb.2007.08.011 pubmed: 17850815
Romanel, A., Zhang, T., Elemento, O. & Demichelis, F. EthSEQ: ethnicity annotation from whole exome sequencing data. Bioinformatics 33, 2402–2404 (2017).
pmcid: 5818140 doi: 10.1093/bioinformatics/btx165 pubmed: 28369222
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2019).
doi: 10.1093/bioinformatics/btp352
Yachida, S. et al. Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system. Cancer Discov. 12, 692–711 (2022).
pmcid: 9394397 doi: 10.1158/2159-8290.CD-21-0669 pubmed: 34880079
Olshen, A. B., Venkatraman, E. S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557–572 (2004).
doi: 10.1093/biostatistics/kxh008 pubmed: 15475419
Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131–e131 (2016).
pmcid: 5027494 doi: 10.1093/nar/gkw520 pubmed: 27270079
Nakamura, H. et al. Genomic spectra of biliary tract cancer. Nat. Genet. 47, 1003–1010 (2015).
doi: 10.1038/ng.3375 pubmed: 26258846
Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
doi: 10.1093/bioinformatics/bts635 pubmed: 23104886
Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
pmcid: 3919509 doi: 10.1038/nature12213 pubmed: 23770567
Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041 (2017).
pmcid: 5720395 doi: 10.1016/j.cell.2017.09.042 pubmed: 29056346
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. B 57, 289–300 (1995).
Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).
pmcid: 4048962 doi: 10.1038/nature12912 pubmed: 24390350
Mularoni, L., Sabarinathan, R., Deu-Pons, J., Gonzalez-Perez, A. & López-Bigas, N. OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations. Genome Biol. 17, 128 (2016).
pmcid: 4910259 doi: 10.1186/s13059-016-0994-0 pubmed: 27311963
Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 575, 210–216 (2019).
pmcid: 6872491 doi: 10.1038/s41586-019-1689-y pubmed: 31645765
Waterhouse, A. et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46, W296–W303 (2018).
pmcid: 6030848 doi: 10.1093/nar/gky427 pubmed: 29788355
Willard, L. et al. VADAR: a web server for quantitative evaluation of protein structure quality. Nucleic Acids Res. 31, 3316–3319 (2003).
pmcid: 168972 doi: 10.1093/nar/gkg565 pubmed: 12824316
Pettersen, E. F. et al. UCSF Chimera: a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
doi: 10.1002/jcc.20084 pubmed: 15264254
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pmcid: 2705234 doi: 10.1093/bioinformatics/btp324 pubmed: 19451168
Van der Auwera, G. A. et al. From FastQ data to high-confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11.10.1–11.10.33 (2013).
Sim, N. L. et al. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 40, W452–W457 (2012).
pmcid: 3394338 doi: 10.1093/nar/gks539 pubmed: 22689647
Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr. Protoc. Hum. Genet. 7, 7.20.1–7.20.41 (2013).
Schwarz, J. M., Cooper, D. N., Schuelke, M. & Seelow, D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat. Methods 11, 361–362 (2014).
doi: 10.1038/nmeth.2890 pubmed: 24681721
Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310–315 (2014).
pmcid: 3992975 doi: 10.1038/ng.2892 pubmed: 24487276
Harrison, S. M. et al. Using ClinVar as a resource to support variant interpretation. Curr. Protoc. Hum. Genet. 89, 8.16.1–8.16.23 (2016).
pubmed: 27037489
Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164–e164 (2010).
pmcid: 2938201 doi: 10.1093/nar/gkq603 pubmed: 20601685
1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 526, 68–74 (2015).
Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
pmcid: 5018207 doi: 10.1038/nature19057 pubmed: 27535533
Petrovski, S., Wang, Q., Heinzen, E. L., Allen, A. S. & Goldstein, D. B. Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet. 9, e1003709 (2013).
pmcid: 3749936 doi: 10.1371/journal.pgen.1003709 pubmed: 23990802
Nagasaki, M. et al. Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals. Nat. Commun. 6, 8018 (2015).
doi: 10.1038/ncomms9018 pubmed: 26292667
Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246–259 (2013).
pmcid: 3588146 doi: 10.1016/j.celrep.2012.12.008 pubmed: 23318258
Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).
pmcid: 4762164 doi: 10.1186/s13059-016-0893-4 pubmed: 26899170
Bjerregaard, A. M., Nielsen, M., Hadrup, S. R., Szallasi, Z. & Eklund, A. C. MuPeXI: prediction of neo-epitopes from tumor sequencing data. Cancer Immunol. Immunother. 66, 1123–1130 (2017).
doi: 10.1007/s00262-017-2001-3 pubmed: 28429069
Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152–1158 (2015).
pmcid: 4747795 doi: 10.1038/nbt.3344 pubmed: 26372948
Xie, C. et al. Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. Proc. Natl Acad. USA 114, 8059–8064 (2017).
doi: 10.1073/pnas.1707945114
Kawaguchi, S., Higasa, K., Shimizu, M., Yamada, R. & Matsuda, F. HLA-HD: an accurate HLA typing algorithm for next-generation sequencing data. Hum. Mutat. 38, 788–797 (2017).
McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271 (2017).
pmcid: 5720478 doi: 10.1016/j.cell.2017.10.001 pubmed: 29107330

Auteurs

Yasushi Totoki (Y)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Mihoko Saito-Adachi (M)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Yuichi Shiraishi (Y)

Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.

Daisuke Komura (D)

Department of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Hiromi Nakamura (H)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Akihiro Suzuki (A)

Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
Genome Science and Medicine Laboratory, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

Kenji Tatsuno (K)

Genome Science and Medicine Laboratory, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

Hirofumi Rokutan (H)

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Natsuko Hama (N)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Shogo Yamamoto (S)

Genome Science and Medicine Laboratory, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

Hanako Ono (H)

Division of Bioinformatics, National Cancer Center Research Institute, Tokyo, Japan.

Yasuhito Arai (Y)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Fumie Hosoda (F)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Hiroto Katoh (H)

Department of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Kenichi Chiba (K)

Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.

Naoko Iida (N)

Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.

Genta Nagae (G)

Genome Science and Medicine Laboratory, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

Hiroki Ueda (H)

Biological Data Science, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

Chen Shihang (C)

Genome Science and Medicine Laboratory, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

Shigeki Sekine (S)

Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.

Hiroyuki Abe (H)

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Sachiyo Nomura (S)

Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Tetsuya Matsuura (T)

Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Eiji Sakai (E)

Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Takashi Ohshima (T)

Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan.

Yasushi Rino (Y)

Department of Surgery, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Khay Guan Yeoh (KG)

Dept of Medicine, National University of Singapore, Singapore, Singapore.

Jimmy So (J)

Dept of Surgery, National University of Singapore, Singapore, Singapore.

Kaushal Sanghvi (K)

Dept of Surgery, Tan Tock Seng Hospital, Singapore, Singapore.

Richie Soong (R)

Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

Akihiko Fukagawa (A)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.

Shinichi Yachida (S)

Department of Cancer Genome Informatics, Graduate School of Medicine, Osaka University, Osaka, Japan.
Division of Genomic Medicine, National Cancer Center Research Institute, Tokyo, Japan.

Mamoru Kato (M)

Division of Bioinformatics, National Cancer Center Research Institute, Tokyo, Japan.

Yasuyuki Seto (Y)

Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Tetsuo Ushiku (T)

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Atsushi Nakajima (A)

Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Hitoshi Katai (H)

Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.

Patrick Tan (P)

Cancer and Stem Cell Biology, Duke-NUS Medical School Singapore, Singapore, Singapore.
Epigenomic and Epitranscriptomic Regulation, Genome Institute of Singapore, Singapore, Singapore.

Shumpei Ishikawa (S)

Department of Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Hiroyuki Aburatani (H)

Genome Science and Medicine Laboratory, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

Tatsuhiro Shibata (T)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan. tshibata@ims.u-tokyo.ac.jp.
Laboratory of Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. tshibata@ims.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH